Cannabidiol: MPF requires explanation on CFM resolution which restricts substance use

The deadline for replying is 15 days; Also warned Anvisa and the Ministry of Health

or Federal Public Ministry (MPF) this Monday, 17, started a procedure to determine the compatibility of the resolution of Federal Council of Medicine (FCM) which limits its use cannabidiol (CBD), a compound derived from the cannabis sativa (marijuana) plant, with the fundamental social right to health under the Federal Constitution. The body asked CFM about the changes, which reacted after publication, within 15 days. He also asked for clarification, within the same term, to art National Health Surveillance Agency (Anvisa) it’s at Ministry of Health.

In addition to limiting the possibilities of prescribing cannabidiol, the ruling published by the CFM last week prohibited doctors from giving lectures and courses on the use of this and other products derived from cannabis outside of the scientific environment. For the standardthe council authorizes the medical profession to prescribe the product only for the treatment of childhood and adolescent epilepsy associated with Dravet and Lennox-Gastaut syndromes and tuberous sclerosis complex – and only in cases where the patient has not shown good results with conventional treatments.

In this way, the MPF requested documents from the CFM that translate the scientific evidence supporting the recent standard. Anvisa has requested documents that demonstrate the scientific evidence in support of the resolutions in force on the subject: RDC n. 327, of December 2019, and RDC n. 335, of January 2020. In addition to asking the Ministry of Health for information on the administrative, financial and technical consequences of the Anvisa and CFM resolutions on the SUS. The response period is 15 days.

Measure reactions faced after posting

as shown on Estadio the last day 14, doctors, activists, politicians and organizations related to the use of cannabis reacted to the publication of the rule. To date, WeCann Academy neurosurgeon Patricia Montagner, responsible for monitoring more than 1000 medical cannabis users, said the measure “is a loss of opportunity for the Federal Council of Medicine to assume its role of giving the north to the subject in Brazil, in an ethical and scientifically appropriate way “.

“From a scientific point of view, the resolution simply ignored the various scientific advances (and regulate) linked to this topic that have occurred in recent years, in Brazil and in dozens of other countries around the world. The bibliographic references used for the publication of the Resolution date back to 2014. That is, eight years ago. From the point of view of medical ethics, the resolution represents much more than a setback, it represents a violation of legal and constitutional rights “, added the doctor.

Activist and patient Juliana Paolinelli Novaes, 43, stressed that the resolution continues to address the use of cannabidiol in childhood and adolescence in specific cases of epilepsy, but asks: “And when a person goes beyond the adolescence? Do you miss the chance of treatment? ” Juliana also regrets the prohibition on “in kind” prescription. “It is a great option for immediate effect in spasms and neuropathic pain crises, as, for example, in my case,” she said.

BRCANN (Brazilian Association of Cannabinoid Industry) expressed itself in a statement, deploring the new resolution. “This, in our opinion, violates the legal principle of medical autonomy and is unconstitutional, as it violates the free exercise of the profession, guaranteed by Article 13 of the Charter”, reads the note published last week.

+The best content in your email for free. Choose your favorite Earth Newsletter. Click here!

Source: Terra

Benjamin

Benjamin Smith is a fashion journalist and author at Gossipify, known for his coverage of the latest fashion trends and industry insights. He writes about clothing, shoes, accessories, and runway shows, providing in-depth analysis and unique perspectives. He’s respected for his ability to spot emerging designers and trends, and for providing practical fashion advice to readers.